Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AG-221

Known as: IDH2 Inhibitor AG-221 
An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, AG-221… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Somatic mutations in the isocitrate dehydrogenase 2 gene (IDH2) contribute to the pathogenesis of acute myeloid leukaemia (AML… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in multiple hematologic and solid tumors… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Genomic studies in acute myeloid leukemias (AML) have identified mutations that drive altered DNA methylation, including TET2 and… Expand
Is this relevant?
Review
2017
Review
2017
Opinion statementApproximately 40–45% of younger and 10–20% of older adults with acute myeloid leukemia (AML) will be cured with… Expand
  • table 2
Is this relevant?
2017
2017
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML 
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Introduction : IDH2 mutations (m IDH2 ) are recurrent in ~5% of patients (pts) with MDS and ~15% of pts with acute myeloid… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Background: There is an unmet need fortreatments (Tx) for myeloid malignancies, particularly relapsed/refractory (RR) AML, that… Expand
Is this relevant?
2014
2014
INTRODUCTION:Somatic mutations in the metabolic enzymes isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer gain-of-function… Expand
Is this relevant?
2014
2014
Background: Cancer metabolism represents an emerging field of novel cancer target discovery. Somatic point mutations in the… Expand
Is this relevant?
2013
2013
Somatic point mutations in isocitrate dehydrogenase 1/2 (IDH1/2) confer a gain-of-function in cancer cells resulting in the… Expand
Is this relevant?